Every 10-Q that GREEN PLANET BIOENGR (GPLB) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow GPLB and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full GPLB filings page.
Green Planet Bioengineering Co., Ltd., a Delaware company operating as a public reorganized shell, reported unaudited results for the quarter and six months ended June 30, 2026. The company has no assets or cash, and no active business operations; expenses are primarily accounting and filing fees.
For the six months ended June 30, 2026, Green Planet recorded a net loss of $16,849, compared with a net loss of $10,945 for the same period in 2025. At June 30, 2026, current liabilities totaled $517,825, including $513,975 due to a related party, resulting in a working capital deficit of $517,825 and an accumulated deficit of $1,147,445. The capital structure consists of 20,006,402 common shares outstanding and authorized but unissued preferred stock with high voting and conversion rights.
Management states there is substantial doubt about the company’s ability to continue as a going concern, as it is entirely dependent on interest-free, on-demand advances from a related party of the majority stockholder. Subsequent to June 30, 2026, this related party advanced an additional $3,850 to fund ongoing expenses. Disclosure controls and procedures are described as effective.
Green Planet Bioengineering Co., Ltd. remains an inactive public shell company with no operating business. For the quarter ended March 31, 2026, it reported a net loss of $10,944, driven by administrative expenses and interest, with the basic and diluted loss per share rounded to less than $0.01.
The balance sheet shows no assets or cash and total current liabilities of $511,920, including $501,321 due to a related party, resulting in a stockholders’ deficit of $511,920. Management discloses a working capital deficit, accumulated deficit of $1,141,540, and expresses substantial doubt about the company’s ability to continue as a going concern, noting continued dependence on financing from a related party. Subsequent to quarter-end, the related party advanced an additional $3,850. No legal proceedings, off‑balance sheet arrangements, or commitments and contingencies are reported, and management concludes disclosure controls and procedures are effective.
Green Planet Bioengineering (GPLB) filed its Q3 2025 report, remaining a public shell with no active operations and disclosing substantial doubt about its ability to continue as a going concern.
For the quarter ended September 30, 2025, the company recorded a net loss of $8,599, bringing the nine‑month net loss to $19,544, driven by administrative costs. As of September 30, 2025, it reported zero cash, a working capital deficit of $484,678, and an accumulated deficit of $1,114,298. Current liabilities include $479,148 due to a related party, which is interest‑free, unsecured, and payable on demand. A subsequent event notes an additional $5,530 advanced by the related party after October 1, 2025.
Common shares outstanding were 20,006,402 as of November 14, 2025. Management states disclosure controls and procedures were effective. The company continues to rely on related‑party funding while it seeks potential business combinations.